ARCHIVES

Three Nominated To ET2; NCI Seeks Clinical Applications

This article is from The Cancer Letter archive.

Vol. 17 No. 21 | May 24, 1991

Download PDF Visit The Full Archive

Related Articles

Sorafenib Targets AML Driven By Mutant FLT3 Gene

February 29, 2008

DCBD Board Okays Concept for Animal Holding Recompetition

December 5, 1986

Cancer Advocates Ask House By Byspass Budget; NCCR’s Day Calls For $380 Mil. Minimum Increase

March 12, 1993

Kadcyla Extends Median PFS In Open-Label Phase III Trial

October 25, 2013

Tobacco Control Bill Requires Stronger Warnings

August 10, 1990

NCI To Voluntarily Spends $196 Million On Breast Cancer; Will Require Reallocation

November 13, 1992